Advicenne Secures Five-Year Marketing Authorization Renewal for Sibnayal in European Union
Key Insights
The European Medicines Agency (search) has renewed Advicenne's marketing authorization for Sibnayal, a fixed combination of potassium citrate and potassium bicarbonate, for treating distal renal tubular acidosis (search) in the European Union starting January 2026.
This mandatory five-year renewal definitively validates the marketing authorization and represents a major milestone for the continued commercial development of Sibnayal in Europe.
The renewal is part of Advicenne's expanding regulatory program, which includes marketing authorization obtained in Saudi Arabia in July 2025 and a recent registration application filed with the US Food and Drug Administration (search).
French pharmaceutical company Advicenne has successfully secured the renewal of its marketing authorization for Sibnayal in the European Union, marking a significant regulatory milestone for the rare kidney disease treatment. The European Medicines Agency (search) renewed the marketing authorization for Sibnayal starting in January 2026, providing continued commercial validation for the specialized therapy.
Regulatory Milestone Validates Long-term Commercial Strategy
The renewal, which is mandatory five years after the initial issuance, definitively validates the marketing authorization for Sibnayal. This regulatory achievement represents a major milestone for the continued commercial development of Sibnayal in Europe, reinforcing the treatment's established position in the rare disease market.
Sibnayal is a fixed combination of potassium citrate and potassium bicarbonate specifically developed for the treatment of distal renal tubular acidosis (search) (dRTA). The therapy addresses a critical unmet need in nephrology, where treatment options for rare kidney diseases (search) remain limited.
Expanding Global Regulatory Footprint
The European renewal is part of Advicenne's busy regulatory program that demonstrates the company's commitment to expanding global access to Sibnayal. The company obtained marketing authorization in the Kingdom of Saudi Arabia in July 2025, extending the treatment's availability beyond European markets.
More recently, Advicenne filed a registration application with the US Food and Drug Administration (search), potentially opening access to the significant American market for patients with distal renal tubular acidosis (search).
Comprehensive Development Pipeline
Advicenne, a specialty pharmaceutical company founded in 2007, specializes in developing innovative treatments in nephrology with a focus on rare kidney diseases (search). The company's lead product Sibnayal (ADV7103) has received marketing approval for distal renal tubular acidosis (search) in both the European Union and Great Britain.
The development program for ADV7103 extends beyond its current indication, with the therapy currently in late-stage development for cystinuria (search) in Europe. Additionally, the company is advancing clinical programs for both distal renal tubular acidosis (search) and cystinuria in the United States and Canada, potentially expanding the treatment's therapeutic applications.
Company Profile and Market Position
Headquartered in Paris, Advicenne has been publicly traded since 2017, initially on the Euronext Paris stock exchange before transferring to Euronext Growth Paris on March 30, 2022. The company operates under the ticker symbol ALDVI (FR0013296746) and maintains its focus on addressing the specialized needs of patients with rare kidney diseases (search).
The successful renewal of Sibnayal's marketing authorization in the European Union reinforces Advicenne's position as a dedicated player in the rare disease pharmaceutical sector, with a growing international regulatory presence supporting its commercial objectives.